What diseases does ibrutinib capsules mainly treat and its scope of application?

Ibrutinib (also known as Ibrutinib) is an oral Bruton's tyrosine kinase (BTK) inhibitor. It is a targeted therapy drug and is mainly used to treat a series of hematological malignancies derived from B cells. It effectively interferes with the survival and proliferation of tumor cells by inhibiting the BTK signaling pathway, and has shown good therapeutic effects in multiple lymphatic system diseases. Ibrutinib is currently widely used in the standard treatment regimen for adult patients and is an important breakthrough in the field of hematological tumors.

Ibrutinib is most commonly used to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), especially for patients with high-risk genetic characteristics (such as 17p deletion). It can delay disease progression and improve progression-free survival, and is considered one of the first-line treatment options for such patients. In addition, it can also be used as a monotherapy for initial treatment or after relapse, or in combination with other drugs, with high flexibility.

In addition toCLL/SLL, ibrutinib is also suitable for mantle cell lymphoma (MCL), especially for patients with relapsed or refractory MCL. Ibrutinib provides new treatment opportunities. For these patients, traditional chemotherapy regimens have limited effects, while ibrutinib can effectively prolong the remission time through targeted mechanisms, and some patients even achieve long-term control. In addition, ibrutinib is also approved for the treatment of Waldenstrom's macroglobulinemia (WM), which can significantly improve the quality of life by improving patients' blood indicators and symptoms.

In summary, the applicable scope of ibrutinib capsules mainly includes CLL, SLL, MCL and WM and other B cell-related malignant tumors. As a targeted drug, it has the advantages of oral convenience, relatively low side effects, and significant efficacy. However, it is still necessary to regularly monitor blood indicators, liver and kidney functions, etc. during use to avoid accumulation of side effects, and adjust the dosage according to individual conditions. Standardized medication under the guidance of a doctor can better unleash the therapeutic potential of ibrutinib.

Reference materials:https://www.drugs.com